𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Guanosine improves motor behavior, reduces apoptosis, and stimulates neurogenesis in rats with parkinsonism

✍ Scribed by Caixin Su; Nada Elfeki; Patrizia Ballerini; Iolanda D'Alimonte; Christian Bau; Renata Ciccarelli; Francesco Caciagli; Joseph Gabriele; Shucui Jiang


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
918 KB
Volume
87
Category
Article
ISSN
0360-4012

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) caused by an abnormal rate of apoptosis. Endogenous stem cells in the adult mammalian brain indicate an innate potential for regeneration and possible resource for neuroregeneration in PD. We previously showed that guanosine prevents apoptosis even when administered 48 hr after the toxin 1‐methyl‐4‐phenylpyridinium (MPP^+^). Here, we induced parkinsonism in rats with a proteasome inhibitor. Guanosine treatment reduced apoptosis, increased tyrosine hydroxylase–positive dopaminergic neurons and expression of tyrosine hydroxylase in the SNc, increased cellular proliferation in the SNc and subventricular zone, and ameliorated symptoms. Proliferating cells in the subventricular zone were nestin‐positive adult neural progenitor/stem cells. Fibroblast growth factor‐2‐expressing cells were also increased by guanosine. Thus, guanosine protected cells from apoptosis and stimulated “intrinsic” adult progenitor/stem cells to become dopaminergic neurons in rats with proteasome inhibitor–induced PD. The cellular/molecular mechanisms underlying these effects may open new avenues for development of novel therapeutics for PD. © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Quantitative measurements of alternating
✍ Ana Lisa Taylor Tavares; Gregory S.X.E Jefferis; Mandy Koop; Bruce C. Hill; Trev 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB 👁 1 views

## Abstract The Unified Parkinson's Disease Rating Scale (UPDRS) is the primary outcome measure in most clinical trials of Parkinson's disease (PD) therapeutics. Each subscore of the motor section (UPDRS III) compresses a wide range of motor performance into a coarse‐grained scale from 0 to 4; the